Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1201 participants.

Also called NCT02648204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,201 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02648204
  • EudraCT 2014-005375-91
Main results
  • Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial The lancet. Diabetes & endocrinology, 2018-04 DOI, PubMed 29397376

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Croatia, Finland, Germany, Greece, Hong Kong SAR China, India, Ireland, Latvia, Lithuania, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02648204. Randomized; no masking; primary purpose treatment. Start 2016-01-06 (actual); primary completion 2017-04-10 (actual). Results posted on 2018-05-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Acronym
SUSTAIN 7
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
Dulaglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02648204
Content hash
7aefaaed1ecdfe44f79c138cd40c586be238aa63db91b1a2434689b5d17bddde